| Stacey Hopkins, | |
|
1257 Cranston St, Cranston, RI 02920-7315 | |
| (401) 943-5817 | |
| Not Available |
| Full Name | Stacey Hopkins |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse - Psychiatric/mental Health |
| Location | 1257 Cranston St, Cranston, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427666841 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163WP0808X | Registered Nurse - Psychiatric/mental Health | RN57858 (Rhode Island) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Stacey Hopkins, 98 Station St, Coventry, RI 02816-5770 Ph: (401) 602-1835 | Stacey Hopkins, 1257 Cranston St, Cranston, RI 02920-7315 Ph: (401) 943-5817 |
News Archive
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix™ OOC Multi-Organ MPS.
Canadian Prime Minister Stephen Harper and Tanzanian President Jakaya Kikwete were in Geneva on Wednesday to open a meeting aimed at "developing a framework" to monitor the implementation of a $40 billion U.N. maternal and child health initiative, according to CBC News. Harper and Kikwete are co-chairs of a commission that is charged with ensuring accountability for the pledges.
Researchers have identified a mechanism by which cells undergo reprogramming in live mice, a phenomenon that had previously been poorly understood.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.
› Verified 3 days ago
Rebecca Stevenson, APRN Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 1150 Reservoir Ave Ste 203, Cranston, RI 02920 Phone: 401-259-0340 | |
Venus Nazario Ramos, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 84 Waldron Ave, Cranston, RI 02910 Phone: 401-413-5460 | |
Mrs. Janis M Denuccio, RNC Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1090 New London Ave, Cranston, RI 02920 Phone: 401-463-5778 Fax: 401-463-3582 | |
Ms. Kira E Provost, RN, LCMT Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1145 Reservoir Ave, Suite 300, Cranston, RI 02920 Phone: 401-943-2500 Fax: 401-942-2227 | |
Eniayo Egberongbe, Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 1150 Reservoir Ave Ste 203, Cranston, RI 02920 Phone: 401-259-0340 Fax: 401-259-0340 | |
Heidi Gay, RN, BSN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 101 Wheeler Ave, Cranston, RI 02905 Phone: 401-578-4677 | |
Marie Margaret Mccoole, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 75 Sockanosset Cross Rd, Suite 301, Cranston, RI 02920 Phone: 401-228-3984 Fax: 401-415-8880 |